Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

O. Fiala, M. Pesek, J. Skrickova, V. Kolek, F. Salajka, M. Tomiskova, M. Satankova, J. Kultan, J. Kuliskova, M. Svaton, M. Hrnciarik, K. Hejduk, R. Chloupkova, O. Topolcan, H. Hornychova, M. Nova, A. Ryska, J. Finek,

. 2017 ; 39 (2) : 1010428317691186.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013262

Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013262
003      
CZ-PrNML
005      
20200212163257.0
007      
ta
008      
170413s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1010428317691186 $2 doi
035    __
$a (PubMed)28218046
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fiala, Ondrej $u 1 Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. 2 Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
245    10
$a Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy / $c O. Fiala, M. Pesek, J. Skrickova, V. Kolek, F. Salajka, M. Tomiskova, M. Satankova, J. Kultan, J. Kuliskova, M. Svaton, M. Hrnciarik, K. Hejduk, R. Chloupkova, O. Topolcan, H. Hornychova, M. Nova, A. Ryska, J. Finek,
520    9_
$a Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x biosyntéza $7 D014408
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x metabolismus $x patologie $7 D002289
650    _2
$a DNA vazebné proteiny $x biosyntéza $7 D004268
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a nádory plic $x farmakoterapie $x metabolismus $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a pemetrexed $x aplikace a dávkování $7 D000068437
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pesek, Milos $u 3 Department of Pneumology and Phthisiology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Skrickova, Jana $u 4 Department of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech Republic.
700    1_
$a Kolek, Vitezslav $u 5 Department of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Salajka, Frantisek $u 6 Department of Pneumology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Tomiskova, Marcela $u 4 Department of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech Republic.
700    1_
$a Satankova, Monika $u 4 Department of Respiratory Diseases and TB, Masaryk University Medical School and Teaching Hospital, Brno, Czech Republic.
700    1_
$a Kultan, Juraj $u 5 Department of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Kuliskova, Jana $u 5 Department of Pneumology and Tuberculosis, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Svatoň, Martin $u 2 Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. $7 xx0224192
700    1_
$a Hrnciarik, Michal $u 6 Department of Pneumology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Hejduk, Karel $u 7 Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0227632
700    1_
$a Chloupkova, Renata $u 7 Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Topolcan, Ondrej $u 8 Department of Nuclear Medicine, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Hornychova, Helena $u 9 The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Nova, Marketa $u 9 The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Ryska, Ales $u 9 The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Finek, Jindrich $u 1 Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
773    0_
$w MED00008757 $t Tumour biology the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 39, č. 2 (2017), s. 1010428317691186
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28218046 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20200212163652 $b ABA008
999    __
$a ok $b bmc $g 1199727 $s 974040
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 39 $c 2 $d 1010428317691186 $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace